- Home
- AQST vs MRSN Comparison
AQST vs MRSN Comparison
Compare AQST & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- MRSN
- Stock Information
- Founded
- AQST 2004
- MRSN 2001
- Country
- AQST United States
- MRSN United States
- Employees
- AQST N/A
- MRSN N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- MRSN Health Care
- Exchange
- AQST Nasdaq
- MRSN Nasdaq
- Market Cap
- AQST 285.4M
- MRSN 252.0M
- IPO Year
- AQST 2018
- MRSN 2017
- Fundamental
- Price
- AQST $3.10
- MRSN $0.62
- Analyst Decision
- AQST Strong Buy
- MRSN Buy
- Analyst Count
- AQST 8
- MRSN 6
- Target Price
- AQST $10.38
- MRSN $6.00
- AVG Volume (30 Days)
- AQST 1.5M
- MRSN 7.3M
- Earning Date
- AQST 03-04-2025
- MRSN 02-26-2025
- Dividend Yield
- AQST N/A
- MRSN N/A
- EPS Growth
- AQST N/A
- MRSN N/A
- EPS
- AQST N/A
- MRSN N/A
- Revenue
- AQST $58,900,000.00
- MRSN $34,837,000.00
- Revenue This Year
- AQST $18.44
- MRSN N/A
- Revenue Next Year
- AQST N/A
- MRSN N/A
- P/E Ratio
- AQST N/A
- MRSN N/A
- Revenue Growth
- AQST 22.56
- MRSN N/A
- 52 Week Low
- AQST $2.24
- MRSN $0.56
- 52 Week High
- AQST $6.23
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- AQST 34.77
- MRSN 20.37
- Support Level
- AQST $2.96
- MRSN $0.56
- Resistance Level
- AQST $3.30
- MRSN $1.45
- Average True Range (ATR)
- AQST 0.21
- MRSN 0.14
- MACD
- AQST 0.01
- MRSN -0.06
- Stochastic Oscillator
- AQST 16.87
- MRSN 6.49
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.